123 related articles for article (PubMed ID: 38159687)
41. New fluorescence-based high-throughput screening assay for small molecule inhibitors of tyrosyl-DNA phosphodiesterase 2 (TDP2).
Ribeiro CJA; Kankanala J; Shi K; Kurahashi K; Kiselev E; Ravji A; Pommier Y; Aihara H; Wang Z
Eur J Pharm Sci; 2018 Jun; 118():67-79. PubMed ID: 29574079
[TBL] [Abstract][Full Text] [Related]
42. Novel TDP2-ubiquitin interactions and their importance for the repair of topoisomerase II-mediated DNA damage.
Rao T; Gao R; Takada S; Al Abo M; Chen X; Walters KJ; Pommier Y; Aihara H
Nucleic Acids Res; 2016 Dec; 44(21):10201-10215. PubMed ID: 27543075
[TBL] [Abstract][Full Text] [Related]
43. Ubiquitin stimulated reversal of topoisomerase 2 DNA-protein crosslinks by TDP2.
Schellenberg MJ; Appel CD; Riccio AA; Butler LR; Krahn JM; Liebermann JA; Cortés-Ledesma F; Williams RS
Nucleic Acids Res; 2020 Jun; 48(11):6310-6325. PubMed ID: 32356875
[TBL] [Abstract][Full Text] [Related]
44. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
[TBL] [Abstract][Full Text] [Related]
45. TDP2 suppresses chromosomal translocations induced by DNA topoisomerase II during gene transcription.
Gómez-Herreros F; Zagnoli-Vieira G; Ntai I; Martínez-Macías MI; Anderson RM; Herrero-Ruíz A; Caldecott KW
Nat Commun; 2017 Aug; 8(1):233. PubMed ID: 28794467
[TBL] [Abstract][Full Text] [Related]
46. Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage.
Malik M; Nitiss KC; Enriquez-Rios V; Nitiss JL
Mol Cancer Ther; 2006 Jun; 5(6):1405-14. PubMed ID: 16818498
[TBL] [Abstract][Full Text] [Related]
47. Tyrosyl-DNA phosphodiesterase 2 (TDP2) repairs topoisomerase 1 DNA-protein crosslinks and 3'-blocking lesions in the absence of tyrosyl-DNA phosphodiesterase 1 (TDP1).
Tsuda M; Kitamasu K; Kumagai C; Sugiyama K; Nakano T; Ide H
DNA Repair (Amst); 2020; 91-92():102849. PubMed ID: 32460231
[TBL] [Abstract][Full Text] [Related]
48. Antitumor activity of XR5944, a novel and potent topoisomerase poison.
Stewart AJ; Mistry P; Dangerfield W; Bootle D; Baker M; Kofler B; Okiji S; Baguley BC; Denny WA; Charlton PA
Anticancer Drugs; 2001 Apr; 12(4):359-67. PubMed ID: 11335793
[TBL] [Abstract][Full Text] [Related]
49. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
50. DNA-PK inhibition extends the therapeutic effects of Top2 poisoning to non-proliferating cells, increasing activity at a cost.
Wang T; Kyle AH; Baker JHE; Liu NA; Banáth JP; Minchinton AI
Sci Rep; 2023 Aug; 13(1):12429. PubMed ID: 37528151
[TBL] [Abstract][Full Text] [Related]
51. Topoisomerase II-mediated DNA damage is differently repaired during the cell cycle by non-homologous end joining and homologous recombination.
de Campos-Nebel M; Larripa I; González-Cid M
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20824055
[TBL] [Abstract][Full Text] [Related]
52. ZATT (ZNF451)-mediated resolution of topoisomerase 2 DNA-protein cross-links.
Schellenberg MJ; Lieberman JA; Herrero-Ruiz A; Butler LR; Williams JG; Muñoz-Cabello AM; Mueller GA; London RE; Cortés-Ledesma F; Williams RS
Science; 2017 Sep; 357(6358):1412-1416. PubMed ID: 28912134
[TBL] [Abstract][Full Text] [Related]
53. Tyrosyl-DNA phosphodiesterase (Tdp1) participates in the repair of Top2-mediated DNA damage.
Nitiss KC; Malik M; He X; White SW; Nitiss JL
Proc Natl Acad Sci U S A; 2006 Jun; 103(24):8953-8. PubMed ID: 16751265
[TBL] [Abstract][Full Text] [Related]
54. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle.
Sehested M; Jensen PB
Biochem Pharmacol; 1996 Apr; 51(7):879-86. PubMed ID: 8651936
[TBL] [Abstract][Full Text] [Related]
55. Myeloperoxidase Enhances Etoposide and Mitoxantrone-Mediated DNA Damage: A Target for Myeloprotection in Cancer Chemotherapy.
Atwal M; Lishman EL; Austin CA; Cowell IG
Mol Pharmacol; 2017 Jan; 91(1):49-57. PubMed ID: 27974636
[TBL] [Abstract][Full Text] [Related]
56. Novel regulation of nuclear factor-YB by miR-485-3p affects the expression of DNA topoisomerase IIα and drug responsiveness.
Chen CF; He X; Arslan AD; Mo YY; Reinhold WC; Pommier Y; Beck WT
Mol Pharmacol; 2011 Apr; 79(4):735-41. PubMed ID: 21252292
[TBL] [Abstract][Full Text] [Related]
57. Mre11 Is Essential for the Removal of Lethal Topoisomerase 2 Covalent Cleavage Complexes.
Hoa NN; Shimizu T; Zhou ZW; Wang ZQ; Deshpande RA; Paull TT; Akter S; Tsuda M; Furuta R; Tsutsui K; Takeda S; Sasanuma H
Mol Cell; 2016 Nov; 64(3):580-592. PubMed ID: 27814490
[TBL] [Abstract][Full Text] [Related]
58. Tyrosyl-DNA phosphodiesterases: rescuing the genome from the risks of relaxation.
Kawale AS; Povirk LF
Nucleic Acids Res; 2018 Jan; 46(2):520-537. PubMed ID: 29216365
[TBL] [Abstract][Full Text] [Related]
59. Etoposide-induced DNA cleavage in human leukemia cells.
Edwards CM; Glisson BS; King CK; Smallwood-Kentro S; Ross WE
Cancer Chemother Pharmacol; 1987; 20(2):162-8. PubMed ID: 2822274
[TBL] [Abstract][Full Text] [Related]
60. ATM inhibitor KU60019 synergistically sensitizes lung cancer cells to topoisomerase II poisons by multiple mechanisms.
Shu J; Wang X; Yang X; Zhao G
Sci Rep; 2023 Jan; 13(1):882. PubMed ID: 36650267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
